PRIMARY OBJECTIVES:~I. Determine the response rate (complete and partial) in patients with previously treated metastatic colorectal cancer treated with VEGF Trap.~II. Determine the incidence of disease stabilization, in terms of 4-month progression-free survival, in patients treated with this drug.~SECONDARY OBJECTIVES:~I. Determine the median survival time of patients treated with this drug. II. Determine the 1-year survival rate and stable disease rate in patients treated with this drug.~III. Determine the response or stable disease duration in patients treated with this drug.~IV. Determine the toxicity of this drug in these patients. V. Determine the time to disease progression in patients treated with this drug.~VI. Determine if changes in free VEGF Trap levels correlate with response or toxicity.~OUTLINE: This is a multicenter, open-label study.~Patients are stratified according to prior bevacizumab treatment (yes vs no). Patients receive VEGF Trap IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood collection at the beginning of each course and at 60 days after completion of study treatment. Samples are analyzed by immunoenzyme techniques to determine the pharmacokinetics of VEGF Trap.~After completion of study treatment, patients are followed at 30 and 60 days and then every 3 months thereafter.
This phase II trial is studying how well VEGF Trap works in treating patients with previously treated metastatic colorectal cancer. VEGF Trap may stop the growth of colorectal cancer by blocking blood flow to the tumor.